BLACK DIAMOND THERAPEUTICS, INC. Diluted Shares Outstanding (Weighted Average)
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Diluted Shares Outstanding (Weighted Average) of 57.37 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-05
- BLACK DIAMOND THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 57.37M shares, a 0.99% increase year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 57.23M shares, a 0.76% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 57.81M shares, a 2.10% increase year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 56.93M shares, a 0.75% increase year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for fiscal 2025 was 57.56M shares, a 4.61% increase from fiscal 2024.
- BLACK DIAMOND THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for fiscal 2024 was 55.03M shares, a 25.19% increase from fiscal 2023.
- BLACK DIAMOND THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for fiscal 2023 was 43.95M shares, a 21.00% increase from fiscal 2022.
- BLACK DIAMOND THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for fiscal 2022 was 36.33M shares, a 0.38% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | 57.37M shares 10-Q · filed 2026-08-05 | 57.30M shares 10-Q · filed 2026-08-05 | 57.47M shares derived: average of 3 quarters · filed 2026-08-05 | 57.33M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 57.23M shares 10-Q · filed 2026-05-07 | 57.52M shares derived: average of 2 quarters · filed 2026-05-07 | 57.32M shares derived: average of 3 quarters · filed 2026-05-07 | 57.19M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | 57.81M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | 57.37M shares derived: average of 2 quarters · filed 2026-03-16 | 57.18M shares derived: average of 3 quarters · filed 2026-08-05 | 57.56M shares 10-K · filed 2026-03-16 |
| 2025-09-30 | 56.93M shares 10-Q · filed 2025-11-06 | 56.87M shares derived: average of 2 quarters · filed 2026-08-05 | 57.48M shares 10-Q · filed 2025-11-06 | 57.01M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | 56.80M shares 10-Q · filed 2026-08-05 | 57.47M shares 10-Q · filed 2026-08-05 | 57.03M shares derived: average of 3 quarters · filed 2026-08-05 | 56.90M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | 57.67M shares 10-Q · filed 2026-05-07 | 57.15M shares derived: average of 2 quarters · filed 2026-05-07 | 56.93M shares derived: average of 3 quarters · filed 2026-05-07 | 56.49M shares derived: average of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | 56.62M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | 56.56M shares derived: average of 2 quarters · filed 2026-03-16 | 56.09M shares derived: average of 3 quarters · filed 2026-03-16 | 55.03M shares 10-K · filed 2026-03-16 |
| 2024-09-30 | 56.51M shares 10-Q · filed 2025-11-06 | 55.83M shares derived: average of 2 quarters · filed 2025-11-06 | 54.50M shares 10-Q · filed 2025-11-06 | 53.80M shares derived: average of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | 55.16M shares 10-Q · filed 2025-08-07 | 53.48M shares 10-Q · filed 2025-08-07 | 52.89M shares derived: average of 3 quarters · filed 2025-08-07 | 52.41M shares derived: average of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | 51.81M shares 10-Q · filed 2025-05-12 | 51.76M shares derived: average of 2 quarters · filed 2025-05-12 | 51.49M shares derived: average of 3 quarters · filed 2025-05-12 | 47.75M shares derived: average of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | 51.72M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 51.33M shares derived: average of 2 quarters · filed 2025-03-06 | 46.39M shares derived: average of 3 quarters · filed 2025-03-06 | 43.95M shares 10-K · filed 2025-03-06 |
| 2023-09-30 | 50.94M shares 10-Q · filed 2024-11-05 | 43.73M shares derived: average of 2 quarters · filed 2024-11-05 | 41.37M shares 10-Q · filed 2024-11-05 | 40.08M shares derived: average of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | 36.52M shares 10-Q · filed 2024-08-06 | 36.50M shares 10-Q · filed 2024-08-06 | 36.46M shares derived: average of 3 quarters · filed 2024-08-06 | 36.43M shares derived: average of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | 36.48M shares 10-Q · filed 2024-05-09 | 36.44M shares derived: average of 2 quarters · filed 2024-05-09 | 36.41M shares derived: average of 3 quarters · filed 2024-05-09 | 36.38M shares derived: average of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | 36.39M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | 36.37M shares derived: average of 2 quarters · filed 2024-03-12 | 36.34M shares derived: average of 3 quarters · filed 2024-03-12 | 36.33M shares 10-K · filed 2024-03-12 |
| 2022-09-30 | 36.35M shares 10-Q · filed 2023-11-06 | 36.32M shares derived: average of 2 quarters · filed 2023-11-06 | 36.30M shares 10-Q · filed 2023-11-06 | 36.29M shares derived: average of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | 36.29M shares 10-Q · filed 2023-08-11 | 36.28M shares 10-Q · filed 2023-08-11 | 36.27M shares derived: average of 3 quarters · filed 2023-08-11 | 36.25M shares derived: average of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | 36.27M shares 10-Q · filed 2023-05-09 | 36.25M shares derived: average of 2 quarters · filed 2023-05-09 | 36.24M shares derived: average of 3 quarters · filed 2023-05-09 | 36.23M shares derived: average of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | 36.23M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | 36.22M shares derived: average of 2 quarters · filed 2023-03-09 | 36.21M shares derived: average of 3 quarters · filed 2023-03-09 | 36.19M shares 10-K · filed 2023-03-09 |
| 2021-09-30 | 36.22M shares 10-Q · filed 2022-11-08 | 36.20M shares derived: average of 2 quarters · filed 2022-11-08 | 36.18M shares 10-Q · filed 2022-11-08 | 36.14M shares derived: average of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | 36.18M shares 10-Q · filed 2022-08-09 | 36.15M shares 10-Q · filed 2022-08-09 | 36.12M shares derived: average of 3 quarters · filed 2022-08-09 | 36.07M shares derived: average of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | 36.12M shares 10-Q · filed 2022-05-11 | 36.08M shares derived: average of 2 quarters · filed 2022-05-11 | 36.03M shares derived: average of 3 quarters · filed 2022-05-11 | 36.00M shares derived: average of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | 36.05M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | 35.99M shares derived: average of 2 quarters · filed 2022-03-17 | 35.96M shares derived: average of 3 quarters · filed 2022-03-17 | 32.91M shares 10-K · filed 2022-03-17 |
| 2020-09-30 | 35.93M shares 10-Q · filed 2021-11-08 | 35.92M shares derived: average of 2 quarters · filed 2021-11-08 | 31.86M shares 10-Q · filed 2021-11-08 | |
| 2020-06-30 | 35.91M shares 10-Q · filed 2021-08-12 | 29.80M shares 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | 23.70M shares 10-Q · filed 2021-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |